Literature DB >> 1549862

Chronic human skin graft rejection in severe combined immunodeficient mice engrafted with human PBL from an HLA-presensitized donor.

T Kawamura1, T Niguma, J H Fechner, R Wolber, M A Beeskau, D A Hullett, H W Sollinger, W J Burlingham.   

Abstract

Mice with severe combined immunodeficiency (C.B-17 scid [SCID]) accepted xenografts of adult human peripheral blood leukocytes injected intraperitoneally as evidenced by production of human immunoglobulin (IgG and IgM), and circulation of human leukocytes in peripheral blood. SCID mice also accepted human split-thickness skin xenografts. Passenger leukocytes present in small numbers in such skin grafts could also recirculate in host peripheral blood and make detectable levels of human immunoglobulin. To test the immunocompetence of the transferred human PBL, SCID mice received a human skin xenograft from a second donor (HLA-mismatched with the PBL donor) either before (n = 6) or after (n = 23) xenografting of PBL. Skin was monitored daily for signs of rejection, and rejection was scored by histology 3-4 weeks after the second graft (PBL or skin) was placed. Of 19 SCID injected with PBL from an HLA presensitized patient (L.G.), 7/19 (37%) rejected a subsequent HLA-mismatched skin xenograft. Two of six SCID (33%) rejected a previously established skin xenograft when PBL were administered afterward. The rejection of the human skin was chronic, of relatively late onset (3-4 weeks), and was characterized grossly by contraction, glassy surface, and thickening. Histopathologic examination showed lymphocyte infiltration into the dermis with endothelial cell cuffing and destruction of capillaries, as well as lymphocyte tagging of the basal epidermis, hyperkeratosis, lymphocyte exocytosis and single epidermal cell necrosis. Immunostaining with monoclonal antibody to human CD2 or mouse CD3 revealed that human, but not mouse T lymphocytes were tagging the dermis/epidermis junction and infiltrating the epidermis of rejecting skin grafts. We conclude that a form of human skin graft rejection may be reproduced in an SCID mouse. The immune status of the transferred cells (sensitized vs. normal) and the lymphocytes ability to recirculate in SCID peripheral blood appear to be factors limiting the rejection process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549862     DOI: 10.1097/00007890-199203000-00032

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras.

Authors:  M Christofidou-Solomidou; S M Albelda; F C Bennett; G F Murphy
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells.

Authors:  C Gysemans; M Waer; J Laureys; J Depovere; D Pipeleers; R Bouillon; C Mathieu
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 3.  Human allograft rejection in humanized mice: a historical perspective.

Authors:  Michael A Brehm; Leonard D Shultz
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

4.  Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.

Authors:  A Tsicopoulos; J Pestel; O Fahy; H Vorng; F Vandenbusche; H Porte; L Eraldi; A Wurtz; H Akoum; Q Hamid; B Wallaert; A B Tonnel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

5.  Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules.

Authors:  H C Yan; I Juhasz; J Pilewski; G F Murphy; M Herlyn; S M Albelda
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

6.  Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse.

Authors:  A G Murray; P Petzelbauer; C C Hughes; J Costa; P Askenase; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

7.  Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model.

Authors:  James M Mathew; Bonnie Blomberg; Camillo Ricordi; Violet Esquenazi; Joshua Miller
Journal:  Hum Immunol       Date:  2008-08-12       Impact factor: 2.850

8.  In vitro preactivated human T cells engraft in SCID mice and migrate to murine lymphoid tissues.

Authors:  N Armstrong; F Cigel; W Borcherding; R Hong; V Malkovska
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

9.  Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity.

Authors:  V Malkovska; F Cigel; B E Storer
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.